The Fertility Industrial Complex

One in six people worldwide experience infertility. In the United States, the use of assisted reproductive technology (ART) like in vitro fertilization (IVF) is surging, with over 91,000 babies born from IVF in 2022 alone. This growing demand creates a massive economic opportunity, and corporations are cashing in.

Enter Progenesis, Inc. They market an expensive add-on to the already costly IVF process: PGT-A testing. They promise to screen embryos for chromosomal abnormalities, helping families select the “best” ones for implantation. They sell it as a shortcut to a healthy baby, a scientific guarantee for people navigating one of the most vulnerable moments of their lives.

A new class-action complaint alleges this promise is built on a foundation of lies. The company is accused of using false, deceptive, and misleading advertising to sell a test that scientific evidence does not support, turning deep personal hope into corporate profit.

The Non-Financial Ledger: A Betrayal of Trust

The damage here isn’t just financial. This is about the weaponization of hope. The lawsuit exposes a business model that preys on the desperation of people who want nothing more than to build a family. Progenesis allegedly sold certainty where there was none, convincing customers to make irreversible decisions based on faulty information.

Think about that. Families, trusting the “97-98% accuracy” claim, may have discarded their only chances of having a biological child. The complaint alleges this test is not only unproven but also inaccurate. The emotional and psychological toll of such an act, engineered by a corporation’s pursuit of profit, is incalculable. It is a profound betrayal that leaves a mark far deeper than an empty bank account.

Legal Receipts: The Case Against Progenesis

The legal filings are direct. They accuse Progenesis of running a business based on material misrepresentations. The company knew its claims were unsupported, yet continued to market its tests to a vulnerable population.

“Plaintiffs and Class members each spent thousands of dollars for a test based on Defendant’s material misrepresentations and omissions.”

Class Action Complaint, Page 2

The complaint highlights that the gatekeepers of American healthcare, the insurance companies, have already rejected these claims. They are not fringe opinions; they are official policies from the largest players in the industry.

United Healthcare has noted that PGT-A is unproven and not medically necessary due to “insufficient evidence of efficacy.”

Class Action Complaint, Page 4, citing United Healthcare Policy effective June 1, 2024

Likewise, another large health insurance company, Aetna, states that PGT-A testing is “experimental, investigational, or unproven.”

Class Action Complaint, Page 4

Societal Impact: Privatizing Pain, Socializing Loss

Economic Predation

This is a story of economic extraction. Because insurance companies refuse to cover PGT-A, the financial burden falls directly on families. Each test is an out-of-pocket expense costing thousands of dollars, paid on top of the already staggering cost of IVF. The lawsuit alleges that Progenesis knowingly exploited this system, directly profiting from a service that medical and insurance authorities have flagged as lacking evidence. This is a direct transfer of wealth from hopeful parents to corporate shareholders.

Public Health Crisis

When a company aggressively markets an unproven medical test, it creates a public health issue. From 2014 to 2021, the use of PGT-A in IVF cycles exploded from 13% to approximately 40%. This growth was not driven by new scientific breakthroughs. According to the complaint, it was driven by corporate marketing. Progenesis and others in the industry effectively normalized a procedure that, according to scientific studies cited in the complaint, offers no statistical benefit for live-birth rates. They created a new, costly, and emotionally fraught standard of care based on a lie.

The Cost, By The Numbers

What Now? The Watchlist and The Resistance

This lawsuit is a critical first step, but accountability requires sustained public pressure. The system that allowed a company to profit from unproven medical claims remains in place. Here is who to watch and what to do.

Leadership On Watch

• Corporate Entity: Progenesis, Inc., headquartered in La Jolla, California. Their entire business model is now under legal scrutiny.

Regulatory Watchlist

• Centers for Disease Control (CDC): The CDC tracks ART success rates. They need to provide clearer public guidance on the efficacy of add-on procedures like PGT-A.
• The American Society of Reproductive Medicine (ASRM): As a professional organization, its guidelines heavily influence clinic practices. Its position on PGT-A should be scrutinized for corporate influence.
• Major Insurance Companies: Companies like United Healthcare and Aetna are already acting as de-facto regulators by refusing to pay. Their research and policy decisions are a valuable source of truth.

Next Steps: From The Ground Up

Legal action is one tool. Collective action is another. Share this story. Talk to friends and family about the predatory nature of the for-profit healthcare industry. Support patient advocacy groups that fight for transparency and evidence-based care. The fight against corporations like Progenesis is a fight for a world where healthcare is a right, not a product to be deceptively marketed to the highest bidder.